摘要
目的探究对乙肝肝硬化患者应用恩替卡韦抗病毒治疗的临床价值。方法选择该院2019年1—12月期间收治的60例乙肝肝硬化患者,随机分为对照组、研究组,各30例,分别以阿德福韦酯治疗、恩替卡韦治疗,比较两组治疗效果。结果①研究组治疗有效率为93.33%,较对照组73.33%高,差异有统计学意义(χ^(2)=4.320,P=0.038);②治疗后研究组天门冬氨酸氨基转移酶(AST)、丙氨酸氨基转移酶(ALT)水平较对照组低,差异有统计学意义(t=11.404、2.590,P<0.05);③治疗后研究组凝血酶原时间较对照组短,差异有统计学意义(t=2.733,P<0.05);④治疗后研究组透明质酸(HA)、人粘连蛋白(LN)、Ⅲ型前胶原氨基端肽(PⅢNP)水平较对照组低,差异有统计学意义(t=7.004、2.429、4.657,P<0.05);⑤研究组不良反应发生率、耐药率分别为16.67%、3.33%,与对照组13.33%、10.00%相近,差异无统计学意义(χ^(2)=0.131、1.071,P>0.05)。结论对乙肝肝硬化患者实施恩替卡韦治疗,效果理想。
Objective To explore the clinical value of entecavir antiviral therapy in patients with hepatitis B liver cirrhosis.Methods The 60 patients with hepatitis B cirrhosis admitted to the hospital from January to December 2019 were selected and randomly divided into a control group and a study group,30 cases in each group,treated with adefovir dipivoxil and entecavir,respectively,to compare the treatment effects of the two groups.Results 1.The effective rate of treatment in the study group was 93.33%,which was higher than 73.33%in the control group,and the difference was statistically significant(χ^(2)=4.320,P=0.038);2.After treatment,the study group aspartate aminotransferase(AST),The level of alanine aminotransferase(ALT)was lower than that of the control group,and the difference was statistically significant(t=11.404,2.590,P<0.05);3.The prothrombin time in the study group was shorter than that of the control group after treatment,and the difference was statistically significant Significance(t=2.733,P<0.05);4.The levels of hyaluronic acid(HA),human adhesion protein(LN)andⅢprocollagen amino type terminal peptide(PⅢNP)in the study group after treatment were lower than those in the control group,and the difference was statistically significant Significance(t=7.004,2.429,4.659,P<0.05);5.The incidence of adverse reactions and drug resistance rates in the study group were 16.67%and 3.33%,respectively,which were similar to 13.33%and 10.00%in the control group,and the difference was not statistically significant(χ^(2)=0.131,1.071,P>0.05).Conclusion Entecavir treatment for patients with hepatitis B liver cirrhosis is effective.
作者
成小娇
CHENG Xiaojiao(Department of Infectious Diseases,Yixing People's Hospital,Yixing,Jiangsu Province,214200 China)
出处
《系统医学》
2021年第11期49-51,共3页
Systems Medicine
关键词
乙肝肝硬化
恩替卡韦
阿德福韦酯
Hepatitis B cirrhosis
Entecavir
Adefovir dipivoxil
